NCT07520175

Brief Summary

The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is: How much does the surgical procedure lower pressure inside the eye and what is the durability of this effect? Participants will return for periodic eye exams for 2 years following surgery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
41mo left

Started Apr 2026

Typical duration for all trials

Geographic Reach
1 country

7 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Apr 2026Dec 2029

First Submitted

Initial submission to the registry

March 31, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 9, 2026

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

July 22, 2026

Status Verified

July 1, 2026

Enrollment Period

2.7 years

First QC Date

March 31, 2026

Last Update Submit

July 20, 2026

Conditions

Keywords

bio-reinforced canaloplastyopen-angle glaucoma

Outcome Measures

Primary Outcomes (1)

  • Mean change in IOP

    Mean change in IOP as compared to baseline without increase in IOP-lowering medications or secondary IOP-lowering surgery

    12 months, 24 months

Other Outcomes (7)

  • Proportion of eyes with ≥ 20% IOP reduction

    12 months, 24 months

  • Proportion of eyes achieving IOP ≥ 20% reduction without glaucoma medication

    12 months, 24 months

  • Mean change in glaucoma medication use

    12 months, 24 months

  • +4 more other outcomes

Study Arms (1)

Bio-reinforced canaloplasty

Participants with OAG who undergo canaloplasty followed by intraluminal placement of minimally manipulated, homologous-use scleral allograft tissue within Schlemm's canal lumen.

Procedure: AlloSpan Canal Platform Bio-Reinforced Canaloplasty

Interventions

A canaloplasty procedure is performed using AlloSpan Canal manual surgical instrumentation. After canaloplasty, minimally manipulated, homologous-use scleral allograft tissue is placed within in the canal-wall region of the Schlemm's canal lumen to provide structural reinforcement.

Bio-reinforced canaloplasty

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with OAG who are determined to need surgical intervention for maintenance of target IOP

You may qualify if:

  • \. Diagnosis of OAG in the study eye and a candidate for bio-reinforced canaloplasty for aqueous outflow enhancement, as determined by investigator

You may not qualify if:

  • \. Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, or neovascular glaucoma in the study eye 2. Previous minimally invasive or filtering glaucoma surgery in the study eye 3. Previous IOP-lowering procedure ≤ 12 weeks prior to bio-reinforced canaloplasty in the study eye 5. Previous investigational, or non-standard of care procedures and/or treatments ≤ 12 weeks prior to bio-reinforced canaloplasty

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

North Valley Eye Care

Chico, California, 95928, United States

Location

North Bay Eye Associates

Petaluma, California, 94954, United States

Location

Twin Cities Eye Consultants

Coon Rapids, Minnesota, 55433, United States

Location

Cataract & Laser Institute

Medford, Oregon, 97504, United States

Location

Scott & Christie Eyecare Associates

Cranberry Township, Pennsylvania, 16066, United States

Location

Key-Whitman Eye Center

Dallas, Texas, 75243, United States

Location

El Paso Eye Surgeons

El Paso, Texas, 79922, United States

Location

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Study Officials

  • Tsontcho Ianchulev, MD, MPH

    Chief Medical Officer

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
24 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2026

First Posted

April 9, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2029

Last Updated

July 22, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations